Labcorp Holdings Inc. (LH)

NYQ – Цена в реальном времени. Валюта: USD

257.35

+2.27 (0.89%)

При закрытии: May 12, 2026, 4:00 PM EDT

257.05

-0.30 (-0.12%)

До открытия: May 13, 2026, 5:03 AM EDT

12.05.2026

Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems

Labcorp's full test menu will be available through Epic's Aura platform Integration builds on the successful deployment of Invitae genetic testing and accelerates access to the latest genetic and specialty diagnostics through Aura Collaboration will help reduce IT complexity, streamline lab ordering and improve access to diagnostic innovation for hospitals and health systems using Epic nationwide BURLINGTON, N.C., May 12, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with Epic, the nation's leading electronic health record (EHR) supporting hospitals and health systems.

08.05.2026

LH vs. CRL: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical Services sector have probably already heard of Labcorp Holdings (LH) and Charles River Laboratories (CRL). But which of these two stocks offers value investors a better bang for their buck right now?

06.05.2026

Here's Why Labcorp (LH) Is a Great 'Buy the Bottom' Stock Now

Labcorp (LH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

30.04.2026

LH Stock Up in Pre-Market on Q1 Earnings & Revenue Beat, 2026 View Up

Labcorp's shares rise after Q1 beats on earnings and revenues, with growth across segments and a higher 2026 outlook signaling continued momentum.

30.04.2026

Labcorp Holdings Inc. (LH) Q1 2026 Earnings Call Transcript

30.04.2026

Labcorp Advances As AI Investments, Core Businesses Drive Growth

Labcorp Holdings (NYSE:LH) shares are up, up 1.46%, on Thursday as the company reported strong first-quarter results and raised its full-year guidance.

30.04.2026

Here's Why Labcorp Holdings (LH) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Видео

No Data

There is no data to display

Пресс-релизы

12.05.2026

Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems

30.04.2026

Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance

Results from Operations for first quarter 2026 versus first quarter 2025: Revenue: $3.54 billion vs. $3.35 billion, up 5.8% Diluted EPS: $3.35 vs.

22.04.2026

Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®

BURLINGTON, N.C., April 22, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only companion diagnostic approved by the U.S. Food and Drug Administration (FDA) to identify patients with platinum-resistant ovarian cancer who may be eligible for Merck's KEYTRUDA®.i KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) are the first FDA-approved PD-1 inhibitors available as part of a complete treatment regimen for eligible patients with platinum-resistant ovarian cancer.ii Helping Patients Access Critical New Treatment Options Approximately 80% of individuals with ovarian cancer experience recurrence after initial therapy, and many develop resistance to platinum-based chemotherapy, leading to limited treatment options and poor survival outcomes.

21.04.2026

d-wise Appoints 2x-CEO, ex-Labcorp Head of Software Solutions to Drive Next Phase of Strategy & Growth

BOSTON--(BUSINESS WIRE)--d-wise (an Instem company), a leader in statistical computing infrastructure and clinical trial transparency, today announced the appointment of Christine Oliver as its President. Christine brings over two decades of executive leadership in clinical technology, most recently serving as CEO of Beaconcure, an AI company focused on automating the clinical data validation process in biometrics. Prior to that, she served as CEO of endpoint Clinical, a market leader in random.

Labcorp Holdings Inc. (LH)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Labcorp Holdings Inc. (LH)

Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems

LH vs. CRL: Which Stock Is the Better Value Option?

Here's Why Labcorp (LH) Is a Great 'Buy the Bottom' Stock Now

LH Stock Up in Pre-Market on Q1 Earnings & Revenue Beat, 2026 View Up

Labcorp Holdings Inc. (LH) Q1 2026 Earnings Call Transcript

Labcorp Advances As AI Investments, Core Businesses Drive Growth

Here's Why Labcorp Holdings (LH) is a Strong Value Stock

Видео

No Data

Пресс-релизы

Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems

Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance

Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®

d-wise Appoints 2x-CEO, ex-Labcorp Head of Software Solutions to Drive Next Phase of Strategy & Growth

Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems

LH vs. CRL: Which Stock Is the Better Value Option?

Here's Why Labcorp (LH) Is a Great 'Buy the Bottom' Stock Now

LH Stock Up in Pre-Market on Q1 Earnings & Revenue Beat, 2026 View Up

Labcorp Holdings Inc. (LH) Q1 2026 Earnings Call Transcript

Labcorp Advances As AI Investments, Core Businesses Drive Growth

Here's Why Labcorp Holdings (LH) is a Strong Value Stock

Видео

No Data

Пресс-релизы

Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems

Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance

Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®

d-wise Appoints 2x-CEO, ex-Labcorp Head of Software Solutions to Drive Next Phase of Strategy & Growth

Search stocks

Labcorp Holdings Inc. (LH)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Labcorp Holdings Inc. (LH)

Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems

LH vs. CRL: Which Stock Is the Better Value Option?

Here's Why Labcorp (LH) Is a Great 'Buy the Bottom' Stock Now

LH Stock Up in Pre-Market on Q1 Earnings & Revenue Beat, 2026 View Up

Labcorp Holdings Inc. (LH) Q1 2026 Earnings Call Transcript

Labcorp Advances As AI Investments, Core Businesses Drive Growth

Here's Why Labcorp Holdings (LH) is a Strong Value Stock

Видео

No Data

Пресс-релизы

Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems

Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance

Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®

d-wise Appoints 2x-CEO, ex-Labcorp Head of Software Solutions to Drive Next Phase of Strategy & Growth

Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems

LH vs. CRL: Which Stock Is the Better Value Option?

Here's Why Labcorp (LH) Is a Great 'Buy the Bottom' Stock Now

LH Stock Up in Pre-Market on Q1 Earnings & Revenue Beat, 2026 View Up

Labcorp Holdings Inc. (LH) Q1 2026 Earnings Call Transcript

Labcorp Advances As AI Investments, Core Businesses Drive Growth

Here's Why Labcorp Holdings (LH) is a Strong Value Stock

Видео

No Data

Пресс-релизы

Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems

Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance

Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®

d-wise Appoints 2x-CEO, ex-Labcorp Head of Software Solutions to Drive Next Phase of Strategy & Growth